Taken together, these data suggest that targeting ARHGEF12 with Y16, synergizing with docetaxel in GC with high ARHGEF12 expression, presents a potential novel therapeutic strategy for treating OM. The gene discussed is ARHGEF12; the disease is ocular melanoma.